A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). (December 2016) - Byers, L.; Gerber, D.; Peguero, J.; Micklem, D.; Yule, M.; Lorens, J.B.